Ark Genomic Revolution ETF (ARKG)

N/A +N/A (N/A)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Phone: 212-426-7040
jaydilks
jaydilks Mar. 20 at 6:30 PM
$ARKG is the edgiest of small caps like $IWM . Whenever there’s panic, it’s time to buy. This headline is nudging you to be more aggressive at buying.
0 · Reply
jaydilks
jaydilks Mar. 19 at 2:58 PM
$ARKG The first sector to go down is the first to recover too. ARKG qualifies. Adding heavily.
0 · Reply
charleswindsor111
charleswindsor111 Mar. 18 at 7:54 PM
$ARKG this etf is bleeding in out the ass
1 · Reply
TCLutz
TCLutz Mar. 17 at 11:45 PM
$ORBS <— We have a solid group of retail analysts doing deep dives over here! Come join us! 💪🫡🔥 $WLD.X $ARKG $BMNR $ETH.X
2 · Reply
goinbananas
goinbananas Mar. 17 at 6:19 PM
$OCGN indeed! Looking pretty damn good on the 5 year. Breaking out and gaping up… $ARKG $NVAX $PFE $MRNA
0 · Reply
jaydilks
jaydilks Mar. 17 at 5:11 PM
$ARKG Highlights from ARK’s Big Ideas with companies that do it.
0 · Reply
goinbananas
goinbananas Mar. 17 at 2:26 PM
$QDEL Interesting… $ARKG $LABU $XBI
0 · Reply
Miralheba
Miralheba Mar. 17 at 1:29 PM
$ARKG $BMNR $ETH.X $ORBS $WLD.X We will wait and sell together Ma man
0 · Reply
TCLutz
TCLutz Mar. 17 at 1:05 PM
$ORBS NEW Form 4 – Kevin O’Donnell (CEO) Filed: March 17, 2026 Company: Eightco Holdings Inc. (ORBS) Insider: Kevin O’Donnell Role: CEO & Director Transaction date: March 12, 2026 ⸻ What he received • 2,250,000 stock options • Exercise price: $1.01 • Expiration: March 11, 2036 • Underlying shares: 2,250,000 These are options (rights to buy shares) — not shares today. ⸻ Vesting schedule • 25% per year over 4 years • First vest: March 2027 Breakdown: • Year 1 → 562,500 • Year 2 → 562,500 • Year 3 → 562,500 • Year 4 → 562,500 Must remain CEO/director to fully vest. ⸻ What this means economically: If ORBS trades above $1.01, the options gain value. IE: • Stock = $2.00 • Profit per share = $0.99 Total potential value: → ~$2.2M if fully vested & exercised ⸻ Transaction type • Code: “A” (Award) • This is compensation, not a purchase ⸻ Dilution impact If exercised: • Adds 2,250,000 shares Relative to ~200M shares: → ~1.1% potential dilution $WLD.X $ARKG $BMNR $ETH.X
0 · Reply
TCLutz
TCLutz Mar. 17 at 12:50 PM
$ORBS These are excellent/extremely bullish terms for the Form-4: 1. 4,000,000 options were granted • Director Lee Thomas Jong received 4,000,000 stock options. • Exercise price: $1.01 per share. 2. Vesting schedule • Vest 25% per year over four years. • First vesting: March 2027. • Must remain a director to vest. 3. Expiration • Options expire 10 years after grant (2036). If the stock stays below $1.01, the options simply expire worthless. $WLD.X $ARKG $BMNR $ETH.X
2 · Reply
Latest News on ARKG
ARKG: Cathie Wood's Biotech Product Is In Rally Mode

Jan 28, 2026, 5:50 PM EST - 7 weeks ago

ARKG: Cathie Wood's Biotech Product Is In Rally Mode

Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch

Jan 21, 2026, 4:58 PM EST - 2 months ago

Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch

ARKB ARKF ARKK ARKQ ARKX

Investing In Health Stocks - How Policy Clarity Is Opening Doors

Nov 11, 2025, 10:13 AM EST - 4 months ago

Investing In Health Stocks - How Policy Clarity Is Opening Doors

AGNG BBC BBH BBP BIB BIS BMED

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 5 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN AZN BIIB BMY GILD

ARKG: I'm Holding Off Buying For These 3 Reasons

Aug 28, 2025, 8:25 AM EDT - 7 months ago

ARKG: I'm Holding Off Buying For These 3 Reasons

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

Aug 14, 2025, 1:02 PM EDT - 7 months ago

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

AMD ARKF ARKK ARKQ ARKW ARKX COIN

ARKG: April's Wash-Out Low Is Encouraging, Healthcare Still Soft

Jul 25, 2025, 9:43 AM EDT - 8 months ago

ARKG: April's Wash-Out Low Is Encouraging, Healthcare Still Soft

Healthcare Sector Checkup As U.S. Looks To Change Regulations

May 30, 2025, 3:30 PM EDT - 10 months ago

Healthcare Sector Checkup As U.S. Looks To Change Regulations

AGNG BBC BBH BBP BIB BIS BMED

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Feb 25, 2025, 11:06 AM EST - 1 year ago

Seeking Stocks With Vitality In The Volatile Healthcare Sector

IBB XLV AGNG BBC BBH BBP BIB

Cathie Wood on DeepSeek, Nvidia, Stock Picks, China, AI

Jan 28, 2025, 6:00 PM EST - 1 year ago

Cathie Wood on DeepSeek, Nvidia, Stock Picks, China, AI

ARKB ARKF ARKK ARKQ ARKW

ARKG: Eyeing Favorable Macro 2025 Turns, Encouraging Momentum Trends

Jan 25, 2025, 7:57 AM EST - 1 year ago

ARKG: Eyeing Favorable Macro 2025 Turns, Encouraging Momentum Trends

Best Healthcare ETFs To Buy Now

Oct 31, 2024, 2:03 PM EDT - 1 year ago

Best Healthcare ETFs To Buy Now

FXH IXJ VHT XBI XLV

Interest Rate Regimes And ARKG: Underperformance Explained

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Interest Rate Regimes And ARKG: Underperformance Explained

ARKG: A Genomics Play But Active Isn't Adding Value

Jun 24, 2024, 1:07 AM EDT - 1 year ago

ARKG: A Genomics Play But Active Isn't Adding Value

BMO Transfers 3 BMO Mutual Fund ETF Series, Managed by ARK Investment Management, to Cboe Canada

Jun 14, 2024, 8:00 AM EDT - 1 year ago

BMO Transfers 3 BMO Mutual Fund ETF Series, Managed by ARK Investment Management, to Cboe Canada

Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April

May 2, 2024, 4:28 PM EDT - 2 years ago

Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April

AGG ARKB BCI BCIM BITO FBTC HODL

ARKG: Massive Potential, But Not Worth The Risk Yet For These 3 Reasons

Mar 25, 2024, 5:22 AM EDT - 2 years ago

ARKG: Massive Potential, But Not Worth The Risk Yet For These 3 Reasons

Cathie Wood Speaks, ARK Investors Should Listen

Mar 9, 2024, 9:37 PM EST - 2 years ago

Cathie Wood Speaks, ARK Investors Should Listen

ARKB ARKF ARKK ARKQ ARKW ARKX ARKY

China-focused ETFs struggle amid fears of another regulatory ‘crackdown'

Jan 18, 2024, 3:23 PM EST - 2 years ago

China-focused ETFs struggle amid fears of another regulatory ‘crackdown'

ASHR BLOK CCEF CQQQ DXJ FXI JETS

Analyzing ARKG's Trading Activity In Q3

Nov 22, 2023, 11:31 PM EST - 2 years ago

Analyzing ARKG's Trading Activity In Q3

How to Find the Best Biotech ETFs

Oct 30, 2023, 4:52 PM EDT - 2 years ago

How to Find the Best Biotech ETFs

IBB XBI

ARKG ETF: An Enticing Play, But Risks Galore

Sep 28, 2023, 11:15 AM EDT - 2 years ago

ARKG ETF: An Enticing Play, But Risks Galore

Cathie Wood Says ARK Funds Are Seeing Flows Coming Back

Jul 17, 2023, 4:57 PM EDT - 2 years ago

Cathie Wood Says ARK Funds Are Seeing Flows Coming Back

ARKF ARKK ARKW

ARKG: A Probable Window Of Opportunity, Depending On Banks And The Fed

Apr 12, 2023, 2:06 AM EDT - 3 years ago

ARKG: A Probable Window Of Opportunity, Depending On Banks And The Fed

Stocks that are cyclical are going to face severe challenges, says ARK Invest's Cathie Wood

Mar 21, 2023, 11:52 AM EDT - 3 years ago

Stocks that are cyclical are going to face severe challenges, says ARK Invest's Cathie Wood

ARKK ARKW

Can Health Care Stocks Outperform Again In 2023?

Jan 11, 2023, 6:09 PM EST - 3 years ago

Can Health Care Stocks Outperform Again In 2023?

AGNG BBC BBH BBP BMED CNCR FBT

ARKG: Despite A Huge Price Loss In 2022, Not The Right Time To Accumulate

Jan 4, 2023, 1:22 PM EST - 3 years ago

ARKG: Despite A Huge Price Loss In 2022, Not The Right Time To Accumulate

ARKG: Market May Ridicule ARK, But You Shouldn't Ignore Their Genomics ETF

Jan 3, 2023, 3:17 PM EST - 3 years ago

ARKG: Market May Ridicule ARK, But You Shouldn't Ignore Their Genomics ETF

jaydilks
jaydilks Mar. 20 at 6:30 PM
$ARKG is the edgiest of small caps like $IWM . Whenever there’s panic, it’s time to buy. This headline is nudging you to be more aggressive at buying.
0 · Reply
jaydilks
jaydilks Mar. 19 at 2:58 PM
$ARKG The first sector to go down is the first to recover too. ARKG qualifies. Adding heavily.
0 · Reply
charleswindsor111
charleswindsor111 Mar. 18 at 7:54 PM
$ARKG this etf is bleeding in out the ass
1 · Reply
TCLutz
TCLutz Mar. 17 at 11:45 PM
$ORBS <— We have a solid group of retail analysts doing deep dives over here! Come join us! 💪🫡🔥 $WLD.X $ARKG $BMNR $ETH.X
2 · Reply
goinbananas
goinbananas Mar. 17 at 6:19 PM
$OCGN indeed! Looking pretty damn good on the 5 year. Breaking out and gaping up… $ARKG $NVAX $PFE $MRNA
0 · Reply
jaydilks
jaydilks Mar. 17 at 5:11 PM
$ARKG Highlights from ARK’s Big Ideas with companies that do it.
0 · Reply
goinbananas
goinbananas Mar. 17 at 2:26 PM
$QDEL Interesting… $ARKG $LABU $XBI
0 · Reply
Miralheba
Miralheba Mar. 17 at 1:29 PM
$ARKG $BMNR $ETH.X $ORBS $WLD.X We will wait and sell together Ma man
0 · Reply
TCLutz
TCLutz Mar. 17 at 1:05 PM
$ORBS NEW Form 4 – Kevin O’Donnell (CEO) Filed: March 17, 2026 Company: Eightco Holdings Inc. (ORBS) Insider: Kevin O’Donnell Role: CEO & Director Transaction date: March 12, 2026 ⸻ What he received • 2,250,000 stock options • Exercise price: $1.01 • Expiration: March 11, 2036 • Underlying shares: 2,250,000 These are options (rights to buy shares) — not shares today. ⸻ Vesting schedule • 25% per year over 4 years • First vest: March 2027 Breakdown: • Year 1 → 562,500 • Year 2 → 562,500 • Year 3 → 562,500 • Year 4 → 562,500 Must remain CEO/director to fully vest. ⸻ What this means economically: If ORBS trades above $1.01, the options gain value. IE: • Stock = $2.00 • Profit per share = $0.99 Total potential value: → ~$2.2M if fully vested & exercised ⸻ Transaction type • Code: “A” (Award) • This is compensation, not a purchase ⸻ Dilution impact If exercised: • Adds 2,250,000 shares Relative to ~200M shares: → ~1.1% potential dilution $WLD.X $ARKG $BMNR $ETH.X
0 · Reply
TCLutz
TCLutz Mar. 17 at 12:50 PM
$ORBS These are excellent/extremely bullish terms for the Form-4: 1. 4,000,000 options were granted • Director Lee Thomas Jong received 4,000,000 stock options. • Exercise price: $1.01 per share. 2. Vesting schedule • Vest 25% per year over four years. • First vesting: March 2027. • Must remain a director to vest. 3. Expiration • Options expire 10 years after grant (2036). If the stock stays below $1.01, the options simply expire worthless. $WLD.X $ARKG $BMNR $ETH.X
2 · Reply
TCLutz
TCLutz Mar. 17 at 12:50 PM
$ORBS Match 16, 5pm: Form 4 – Statement of Changes in Beneficial Ownership Insider: Lee Thomas Jong The filing shows he was granted stock options, not shares: Details: • 4,000,000 stock options • Exercise price: $1.01 per share • Underlying shares: 4,000,000 ORBS • Expiration: March 11, 2036 The options do not vest immediately. They vest: • 25% per year • starting 1 year after the grant date So: • Year 1 → 1,000,000 options vest • Year 2 → another 1,000,000 • Year 3 → another 1,000,000 • Year 4 → final 1,000,000 Important: He must remain a director for them to vest. If ORBS trades above $1.01, the options have value. Example: • Stock = $2.00 • Exercise = $1.01 • Profit per share = $0.99 Potential value if fully vested: $0.99 × 4,000,000 = ~$3.96M This transaction code is “A” (award) — meaning: • Compensation grant • Not an open-market purchase $WLD.X $ARKG $BMNR $ETH.X
0 · Reply
TCLutz
TCLutz Mar. 17 at 12:50 PM
$ORBS BITMINE is positioning ORBS as a strategic partner investment. 💪🫡 Bitmine’s logic is essentially: • Bitmine = ETH treasury + staking platform • ORBS = AI / crypto venture investment vehicle • Both companies share investors (ARK, Kraken ecosystem, etc.). Orbs is the venture capital arm of Bitmine and Bitmine is the war chest treasury! 🔥 $WLD.X $ARKG $BMNR $ETH.X
0 · Reply
TCLutz
TCLutz Mar. 17 at 12:49 PM
$ORBS Eightco Holdings (NASDAQ: ORBS) deployed $75 million in strategic investments as part of its pivot into AI and blockchain: • $50 million into OpenAI (equity stake in the ChatGPT creator, announced March 2026) • $25 million into Beast Industries (MrBeast’s business arm, including $7 million committed for funding within 60 days) This was disclosed alongside ORBS securing $125 million in new institutional funding (led by Bitmine at $75M, plus ARK Invest and Payward at $25M each). The deployments position ORBS at the intersection of frontier AI and creator economy platforms. Shares jumped up to 25% on the news. No further details on exact ownership percentages or follow-on rounds have been released yet. $WLD.X $ARKG $BMNR $ETH.X
0 · Reply
TCLutz
TCLutz Mar. 17 at 12:48 PM
$ORBS March 13: A new Form S-8 was filed March 13, 2026 Eightco filed a Form S-8 registration statement on March 13, 2026 for shares related to an employee/board incentive plan. An S-8 does not issue shares immediately. It registers shares that can be issued under compensation plans such as: • employee stock grants • RSUs • options • director compensation So the filing creates potential dilution, not immediate dilution. The S-8 registers up to ~15 million shares under the company’s equity incentive plan. Those shares can be issued over time as: • RSUs • stock options • equity compensation ORBS currently has roughly ~198M shares outstanding based on recent filings. If the full S-8 pool were eventually issued: • Potential dilution = ~7–8% additional shares But again, this only happens if the awards are granted and vest. $WLD.X $ARKG $BMNR $ETH.X
0 · Reply
TCLutz
TCLutz Mar. 17 at 12:48 PM
$ORBS March 12: I went thru the March 12, 2026 8-K, Exhibit 99.1 PR & the related publicly available SEC filings. I dont see any section that discloses how many ORBS shares were issued, or any collateral pledged in exchange for the $125M of commitments. Here is what the filing says: The 8-K states that ORBS received “$125M in investment commitments” from ARK Investment Management LLC, Bitmine Immersion Technologies Inc & Payward Services Limited d/b/a Kraken. It does not describe those commitments as closed equity purchases, debt financings, convertible not es, or secured loans. The language is just “investment commitments.” The filing’s exhibit list includes only: • Exhibit 99.1 – Press Release dated March 12, 2026 • Exhibit 104 – Cover Page Interactive Data File There are no attached subscription agreements, securities purchase agreements, note documents, pledge agreements, warrant agreements, or registration-rights agreements in that 8-K. $WLD.X $ARKG $BMNR $ETH.X
0 · Reply
TheBullsAndBears
TheBullsAndBears Mar. 16 at 10:15 PM
$ARKG $BMNR $BTC.X $ORBS $WLD.X In other words $ORBS might be the bottom here
0 · Reply
TCLutz
TCLutz Mar. 16 at 9:36 PM
$ORBS These are excellent/extremely bullish terms for the Form-4: 1. 4,000,000 options were granted • Director Lee Thomas Jong received 4,000,000 stock options. • Exercise price: $1.01 per share.  2. Vesting schedule • Vest 25% per year over four years. • First vesting: March 2027. • Must remain a director to vest.  3. Expiration • Options expire 10 years after grant (2036). If the stock stays below $1.01, the options simply expire worthless. $WLD.X $ARKG $BMNR $BTC.X
1 · Reply
TCLutz
TCLutz Mar. 16 at 9:16 PM
$ORBS <— $WLD.X $ARKG $BMNR $BTC.X
0 · Reply
TCLutz
TCLutz Mar. 16 at 9:10 PM
$ORBS LFGGGGGGGGG Exactly what I said would be an extremely bullish filing was just filed!!! $WLD.X $ARKG $BMNR $BTC.X
2 · Reply
TCLutz
TCLutz Mar. 16 at 8:13 PM
$ORBS BITMINE is positioning ORBS as a strategic partner investment. 💪🫡 Bitmine’s logic is essentially: • Bitmine = ETH treasury + staking platform • ORBS = AI / crypto venture investment vehicle • Both companies share investors (ARK, Kraken ecosystem, etc.). Orbs is the venture capital arm of $BMNR and Bitmine is the war chest treasury! 🔥 $WLD.X $ARKG $BMNR $BTC.X
0 · Reply
TCLutz
TCLutz Mar. 16 at 8:13 PM
$ORBS Eightco Holdings (NASDAQ: ORBS) deployed $75 million in strategic investments as part of its pivot into AI and blockchain: • $50 million into OpenAI (equity stake in the ChatGPT creator, announced March 2026) • $25 million into Beast Industries (MrBeast’s business arm, including $7 million committed for funding within 60 days) This was disclosed alongside ORBS securing $125 million in new institutional funding (led by Bitmine at $75M, plus ARK Invest and Payward at $25M each). The deployments position ORBS at the intersection of frontier AI and creator economy platforms. Shares jumped up to 25% on the news. No further details on exact ownership percentages or follow-on rounds have been released yet. $WLD.X $ARKG $BMNR $BTC.X
0 · Reply
TCLutz
TCLutz Mar. 16 at 8:13 PM
$ORBS March 13: A new Form S-8 was filed March 13, 2026 Eightco filed a Form S-8 registration statement on March 13, 2026 for shares related to an employee/board incentive plan. An S-8 does not issue shares immediately. It registers shares that can be issued under compensation plans such as: • employee stock grants • RSUs • options • director compensation So the filing creates potential dilution, not immediate dilution. The S-8 registers up to ~15 million shares under the company’s equity incentive plan. Those shares can be issued over time as: • RSUs • stock options • equity compensation ORBS currently has roughly ~198M shares outstanding based on recent filings. If the full S-8 pool were eventually issued: • Potential dilution = ~7–8% additional shares But again, this only happens if the awards are granted and vest. $WLD.X $ARKG $BMNR $BTC.X
0 · Reply